Augmentation of the antidepressant action of sertraline with triiodothyronine (T3) [liothyronine] and reboxetine: clinical efficacy, adverse effects and predictors of response.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Reboxetine (Primary) ; Sertraline (Primary) ; Liothyronine
- Indications Major depressive disorder
- Focus Pharmacogenomic; Therapeutic Use
- 22 Mar 2013 Biomarkers information updated
- 23 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 24 Jan 2007 New trial record.